Clinical genome study on the individual differences of infliximab-BS(CTH) subjected to Japanese and Korean rheumatoid arthritis patients at large number of facilities (1) Clinical genome study on the drug responsiveness of Japanese rheumatoid arthritis patients towards infliximab-BS(CTH)
Not Applicable
Recruiting
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000037837
- Lead Sponsor
- Matsubara Mayflower Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
The patients administered with Infliximab-BS sold by other company is excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SNPs that stipulate drug responsiveness to Infliximab-BS [CTH]
- Secondary Outcome Measures
Name Time Method 1.Comparison of SNPs that stipulate drug responsiveness to Infliximab-BS(CTH) and original medical drug, infliximab (effectiveness and safety) 2.Infliximab trough value and quantity of anti-drug antibody prior to and after the administration of Infliximab-BS(CTH)